Extraintestinal manifestations and complications in IBD

Nature Reviews Gastroenterology and Hepatology

Volumn 10, Issue 10, 2013, Pages 585-595

  Ott, Claudia ^a   Scholmerich, Jurgen ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; 6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; ANALGESIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN INHIBITOR; CALCITONIN; CALCIUM; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYANOCOBALAMIN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; ERYTHROPOIETIN; FOLIC ACID; HEPARIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; IRON; METHOTREXATE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TACROLIMUS; TESTOSTERONE; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VITAMIN D;

ABDOMINAL PAIN; ACNE; ACRODERMATITIS ENTEROPATHICA; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; ALLERGIC PNEUMONITIS; AMYLOIDOSIS; ANEMIA; ANKYLOSING SPONDYLITIS; APHTHOUS STOMATITIS; ARTHRALGIA; ARTHROPATHY; ATAXIA; AUTOIMMUNE HEPATITIS; BRONCHIECTASIS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CALCIUM OXALATE STONE; CATARACT; CHOLELITHIASIS; CHRONIC BRONCHITIS; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CROHN DISEASE; CYANOCOBALAMIN DEFICIENCY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECZEMA; ENTERITIS; EPISCLERITIS; ERYTHEMA NODOSUM; FOLIC ACID DEFICIENCY; GLAUCOMA; GLOMERULONEPHRITIS; GLOSSITIS; GRANULOMATOUS HEPATITIS; GUILLAIN BARRE SYNDROME; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; HYPERHOMOCYSTEINEMIA; HYPOGONADISM; INJECTION SITE REACTION; INTERSTITIAL NEPHRITIS; IRON DEFICIENCY ANEMIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG DISEASE; LUNG FIBROSIS; LUPUS LIKE SYNDROME; MOTOR DYSFUNCTION; MOTOR NEUROPATHY; NAUSEA; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NONALCOHOLIC FATTY LIVER; NONHODGKIN LYMPHOMA; OSTEOARTHROPATHY; OSTEOPENIA; OSTEOPOROSIS; PARESTHESIA; PATHOGENESIS; PERIPHERAL NEUROPATHY; POLYARTHRITIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PSORIASIS; PSYCHOSIS; PYODERMA GANGRENOSUM; PYOSTOMATITIS VEGETANS; REMISSION; REVIEW; SACROILIITIS; SKIN CANCER; SKIN DEFECT; SKIN INFECTION; STOMATITIS; TREMOR; ULCERATIVE COLITIS; URIC ACID STONE; UVEITIS; VENOUS THROMBOEMBOLISM; VOMITING; WHITE MATTER LESION;

BILIARY TRACT DISEASES; COMORBIDITY; EYE DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; LIVER DISEASES; LUNG DISEASES; PREVALENCE; RHEUMATIC DISEASES; SKIN DISEASES;

EID: 84885302360     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.117     Document Type: Review

References (124)

1. Rothfuss, K. S., Stange, E. F. & Herrlinger, K. R. Extraintestinal manifestations and complications in inflammatory bowel diseases. World. J. Gastroenterol. 12, 4819-4831 (2006). (Pubitemid 44323206)
2. Danese, S. et al. Extraintestinal manifestations in inflammatory bowel disease. World. J. Gastroenterol. 11, 7227-7236 (2005). (Pubitemid 43137668)
3. Rankin, G. B., Watts, H. D., Melnyk, C. S. & Kelley, M. L. Jr. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 77, 914-920 (1979). (Pubitemid 9242053)
4. Su, C. G., Judge, T. A. & Lichtenstein, G. R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol. Clin. North Am. 31, 307-327 (2002). (Pubitemid 34733048)
5. Bernstein, C. N., Blanchard, J. F., Rawsthorne, P. & Yu, N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am. J. Gastroenterol. 96, 1116-1122 (2001). (Pubitemid 32319146)
6. Lakatos, L. et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J. Gastroenterol. 9, 2300-2307 (2003). (Pubitemid 37321464)
7. Ricart, E. et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm. Bowel Dis. 10, 207-214 (2004). (Pubitemid 38618248)
8. Ardizzone, S., Puttini, P. S., Cassinotti, A. & Porro, G. B. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 40 (Suppl. 2), S253-S259 (2008). (Pubitemid 351878068)
9. Das, K. M. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig. Dis. Sci. 44, 1-13 (1999). (Pubitemid 29053071)
10. Grant, A. J., Lalor, P. F., Salmi, M., Jalkanen, S. & Adams, D. H. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 359, 150-157 (2002). (Pubitemid 34112549)
11. Salmi, M. & Jalkanen, S. Endothelial ligands and homing of mucosal leukocytes in extraintestinal manifestations of IBD. Inflamm. Bowel Dis. 4, 149-156 (1998). (Pubitemid 128699846)
12. Salmi, M. & Jalkanen S. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. J. Immunol. 166, 4650-4657 (2001). (Pubitemid 32233752)
13. Satsangi, J., Grootscholten, C., Holt, H. & Jewell, D. P. Clinical patterns of familial inflammatory bowel disease. Gut 38, 738-741 (1996). (Pubitemid 26167483)
14. Orchard, T. R. et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 118, 274-278 (2000). (Pubitemid 30067500)
15. Orchard, T. R. et al. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 123, 714-718 (2002). (Pubitemid 34977077)
16. Mallas E G., Mackintosh, P., Asquith, P. & Cooke, W. T. Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27). Gut 17, 906-910 (1976). (Pubitemid 8005667)
17. Roussomoustakaki, M. et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 112, 1845-1853 (1997). (Pubitemid 27240769)
18. Peeters, H. et al. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. Ann. Rheum. Dis. 63, 1131-1134 (2004). (Pubitemid 39120367)
19. Veloso, F. T., Carvalho, J. & Magro, F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J. Clin. Gastroenterol. 23, 29-34 (1996). (Pubitemid 26244497)
20. Brakenhoff, L. K., van der Heijde, D. M., Hommes, D. W., Huizinga, T. W. & Fidder, H. H. The joint-gut axis in inflammatory bowel diseases. J. Crohns Colitis 4, 257-268 (2010).
21. Salvarani, C. et al. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand. J. Gastroenterol. 36, 1307-1313 (2001). (Pubitemid 33027811)
22. de Vlam, K. et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J. Rheumatol. 27, 2860-2865 (2000).
23. Palm, O., Bernklev, T., Moum, B. & Gran, J. T. Non-inflammatory joint pain in patients with inflammatory bowel disease is prevalent and has a significant impact on health related quality of life. J. Rheumatol. 32, 1755-1759 (2005). (Pubitemid 41324817)
24. Palm, O., Moum, B., Jahnsen, J. & Gran, J. T. The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatology (Oxford) 40, 1256-1261 (2001).
25. Orchard, T. R., Wordsworth, B. P. & Jewell, D. P. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 42, 387-391 (1998). (Pubitemid 28197029)
26. Bourikas, L. A. & Papadakis, K. A. Musculoskeletal manifestations of inflammatory bowel disease. Inflamm. Bowel Dis. 15, 1915-1924 (2009).
27. Trikudanathan, G., Venkatesh, P. G. & Navaneethan, U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs 72, 2333-2349 (2012).
28. Van Praet, L., Jacques, P., Van den Bosch, F. & Elewaut, D. The transition of acute to chronic bowel inflammation in spondyloarthritis. Nat. Rev. Rheumatol. 8, 288-295 (2012).
29. Brown, M. A. Progress in the genetics of ankylosing spondylitis. Brief Funct. Genomics 10, 249-257 (2011).
30. Mielants, H. et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J. Rheumatol. 22, 2273-2278 (1995).
31. Brown, M. A. et al. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann. Rheum. Dis. 55, 268-270 (1996). (Pubitemid 26120706)
32. Palm, O., Moum, B., Ongre, A. & Gran, J. T. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J. Rheumatol. 29, 511-515 (2002). (Pubitemid 34202820)
33. Steer, S. et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. J. Rheumatol. 30, 518-522 (2003). (Pubitemid 36301944)
34. Thjodleifsson, B., Geirsson, A. J., Bjornsson, S. & Bjarnason, I. A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genealogic study in Iceland. Arthritis Rheum. 56, 2633-2639 (2007). (Pubitemid 47237281)
35. Clegg, D. O., Reda, D. J. & Abdellatif, M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 42, 2325-2329 (1999). (Pubitemid 30333412)
36. Kefalakes, H., Stylianides, T. J., Amanakis, G. & Kolios, G. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? Eur. J. Clin. Pharmacol. 65, 963-970 (2009).
37. Sandborn, W. J. et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin. Gastroenterol. Hepatol. 4, 203-211 (2006). (Pubitemid 43199691)
38. Reinisch, W. et al. An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment. Pharmacol. Ther. 17, 1371-1380 (2003). (Pubitemid 36774144)
39. Mahadevan, U., Loftus, E. V. Jr, Tremaine, W. J. & Sandborn, W. J. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am. J. Gastroenterol. 97, 910-914 (2002). (Pubitemid 34408247)
40. El Miedany, Y., Youssef, S., Ahmed, I. & El Gaafary, M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am. J. Gastroenterol. 101, 311-317 (2006). (Pubitemid 43381673)
41. Clegg, D. O. Treatment of ankylosing spondylitis. J. Rheumatol. Suppl. 78, 24-31 (2006). (Pubitemid 44360189)
42. Van den Bosch, F., Kruithof, E., De Vos, M., De Keyser, F. & Mielants, H. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 356, 1821-1822 (2000).
43. Ellman, M. H., Hanauer, S., Sitrin, M. & Cohen R. Crohn's disease arthritis treated with infliximab: an open trial in four patients. J. Clin. Rheumatol. 7, 67-71 (2001). (Pubitemid 32323434)
44. Herfarth, H. et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am. J. Gastroenterol. 97, 2688-2690 (2002).
45. Generini, S. et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann. Rheum. Dis. 63, 1664-1669 (2004). (Pubitemid 39573700)
46. Zochling J., van der Heijde, D., Dougados, M. & Braun, J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann. Rheum. Dis. 65, 423-432 (2006).
47. Lakatos, P. L. et al. Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion 86 (Suppl. 1), 28-35 (2012).
48. Thrash, B., Patel, M., Shah, K. R., Boland, C. R. & Menter, A. Cutaneous manifestations of gastrointestinal disease: Part II. J. Am. Acad. Dermatol. 68, 211.e1-211.e33 (2013).
49. Farhi, D. et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore) 87, 281-293 (2008).
50. Freeman, H. J. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease. Can. J. Gastroenterol. 19, 603-606 (2005). (Pubitemid 41723284)
51. Trost, L. B. & McDonnell, J. K. Important cutaneous manifestations of inflammatory bowel disease. Postgrad. Med. J. 81, 580-585 (2005). (Pubitemid 41297914)
52. Timani, S. & Mutasim, D. F. Skin manifestations of inflammatory bowel disease. Clin. Dermatol. 26, 265-273 (2008). (Pubitemid 351978196)
53. Juillerat, P. et al. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review. Dermatology 215, 245-251 (2007). (Pubitemid 47378994)
54. Wollina, U. & Haroske, G. Pyoderma gangraenosum. Curr. Opin. Rheumatol. 23, 50-56 (2011).
55. Farrell, A. M., Black, M. M., Bracka, A. & Bunker, C. B. Pyoderma gangrenosum of the penis. Br. J. Dermatol. 138, 337-340 (1998). (Pubitemid 28114144)
56. Lopez San Roman, A. et al. Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab. Rev. Esp. Enferm. Dig. 96, 420-422 (2004).
57. Fonder, M. A., Cummins, D. L., Ehst, B. D., Anhalt, G. J. & Meyerle, J. H. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J. Burns Wounds 5, e8 (2006).
58. Jose, F. A. & Heyman, M. B. Extraintestinal manifestations of inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 46, 124-133 (2008). (Pubitemid 351161117)
59. Evans, P. E. & Pardi, D. S. Extraintestinal manifestations of inflammatory bowel disease: focus on the musculoskeletal, dermatologic, and ocular manifestations. MedGenMed 9, 55 (2007).
60. Mintz, R., Feller, E. R., Bahr, R. L. & Shah, S. A. Ocular manifestations of inflammatory bowel disease. Inflamm. Bowel Dis. 10, 135-139 (2004). (Pubitemid 38332174)
61. Murphy, C. C. et al. Tumor necrosis factor ? blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111, 352-356 (2004). (Pubitemid 38183244)
62. Navaneethan, U. & Shen, B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm. Bowel Dis. 16, 1598-1619 (2010).
63. Pitchumoni, C. S., Rubin, A. & Das, K. Pancreatitis in inflammatory bowel diseases. J. Clin. Gastroenterol. 44, 246-253 (2010).
64. Broome, U. & Bergquist, A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin. Liver Dis. 26, 31-41 (2006). (Pubitemid 43320725)
65. Venkatesh, P. G., Navaneethan, U. & Shen, B. Hepatobiliary disorders and complications of inflammatory bowel disease. J. Dig. Dis. 12, 245-256 (2011).
66. Kim, W. R., Ludwig, J. & Lindor, K. D. Variant forms of cholestatic diseases involving small bile ducts in adults. Am. J. Gastroenterol. 95, 1130-1138 (2000). (Pubitemid 30263502)
67. Joo, M. et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am. J. Surg. Pathol. 33, 854-862 (2009).
68. Soetikno, R. M., Lin, O. S., Heidenreich, P. A., Young, H. S. & Blackstone, M. O. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest. Endosc. 56, 48-54 (2002). (Pubitemid 41115048)
69. Loftus, E. V. Jr et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54, 91-96 (2005).
70. Talwalkar, J. A. & Lindor, K. D. Primary sclerosing cholangitis. Inflamm. Bowel Dis. 11, 62-72 (2005). (Pubitemid 40340258)
71. Lindor, K. D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N. Engl. J. Med. 336, 691-695 (1997). (Pubitemid 27102683)
72. Eaton, J. E. et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am. J. Gastroenterol. 106, 1638-1645 (2011).
73. Brink, M. A. et al. Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn's disease. Gastroenterology 116, 1420-1427 (1999). (Pubitemid 29258891)
74. Damiao, A. et al. Gallbladder hypokinesia in Crohn's disease. Digestion 58, 458-463 (1997). (Pubitemid 27445614)
75. Pitt, H. A. et al. Increased risk of cholelithiasis with prolonged total parenteral nutrition. Am. J. Surg. 145, 106-112 (1983). (Pubitemid 13167709)
76. Nathan, D. M., Angus, P. W. & Gibson, P. R. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J. Gastroenterol. Hepatol. 21, 1366-1371 (2006). (Pubitemid 44154702)
77. Siegel, C. A., Marden, S. M., Persing, S. M., Larson, R. J. & Sands, B. E. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin. Gastroenterol. Hepatol. 7, 874-881 (2009).
78. Shale, M., Kanfer, E., Panaccione, R. & Ghosh, S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 57, 1639-1641 (2008).
79. Tichelaar, Y. I., Kluin-Nelemans, H. J. & Meijer, K. Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review. Thromb. Haemost. 107, 827-837 (2012).
80. Di Fabio, F., Lykoudis, P. & Gordon, P. H. Thromboembolism in inflammatory bowel disease: an insidious association requiring a high degree of vigilance. Semin. Thromb. Hemost. 37, 220-225 (2011).
81. Koutroubakis, I. E. Therapy insight: Vascular complications in patients with inflammatory bowel disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2, 266-272 (2005). (Pubitemid 40895402)
82. Tsiolakidou, G. & Koutroubakis, I. E. Thrombosis and inflammatory bowel disease-the role of genetic risk factors. World J. Gastroenterol. 14, 4440-4444 (2008).
83. Liang, J. et al. Factor V Leiden and inflammatory bowel disease: a systematic review and meta-analysis. J. Gastroenterol. 46, 1158-1166 (2011).
84. Oussalah, A., Gueant, J. L. & Peyrin-Biroulet, L. Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment. Pharmacol. Ther. 34, 1173-1184 (2011).
85. Yilmaz, A. et al. Pulmonary involvement in inflammatory bowel disease. World J. Gastroenterol. 16, 4952-4957 (2010).
86. Betancourt, S. L., Palacio, D., Jimenez, C. A., Martinez, S. & Marom, E. M. Thoracic manifestations of inflammatory bowel disease. AJR Am. J. Roentgenol. 197, W452-W456 (2011).
87. Basseri, B., Enayati, P., Marchevsky, A. & Papadakis, K. A. Pulmonary manifestations of inflammatory bowel disease: case presentations and review. J. Crohns Colitis 4, 390-397 (2010).
88. Abu-Hijleh, M., Evans, S. & Aswad, B. Pleuropericarditis in a patient with inflammatory bowel disease: a case presentation and review of the literature. Lung 188, 505-510 (2010).
89. Pardi, D. S., Tremaine, W. J., Sandborn, W. J. & McCarthy, J. T. Renal and urologic complications of inflammatory bowel disease. Am. J. Gastroenterol. 93, 504-514 (1998). (Pubitemid 29080994)
90. Oikonomou, K., Kapsoritakis, A., Eleftheriadis, T., Stefanidis, I. & Potamianos, S. Renal manifestations and complications of inflammatory bowel disease. Inflamm. Bowel Dis. 17, 1034-1045 (2011).
91. Oikonomou, K. A., Kapsoritakis, A. N., Stefanidis, I. & Potamianos, S. P. Drug-induced nephrotoxicity in inflammatory bowel disease. Nephron. Clin. Pract. 119, c89-c94 (2011).
92. Fraser, J. S., Muller, A. F., Smith, D. J., Newman, D. J. & Lamb, E. J. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment. Pharmacol. Ther. 15, 1131-1137 (2001). (Pubitemid 32675446)
93. Poulou, A. C. et al. Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid? World J. Gastroenterol. 12, 739-746 (2006). (Pubitemid 43380756)
94. Izzedine, H. et al. Primary chronic interstitial nephritis in Crohn's disease. Gastroenterology 123, 1436-1440 (2002). (Pubitemid 35231642)
95. Herrlinger, K. R. et al. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment. Pharmacol. Ther. 15, 363-369 (2001). (Pubitemid 32187558)
96. Obici, L. & Merlini, G. AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med. Wkly 142, w13580 (2012).
97. Ben-Ami, H. et al. Diagnosis and treatment of urinary tract complications in Crohn's disease: an experience over 15 years. Can. J. Gastroenterol. 16, 225-229 (2002). (Pubitemid 34727587)
98. McConnell, N., Campbell, S., Gillanders, I., Rolton, H. & Danesh, B. Risk factors for developing renal stones in inflammatory bowel disease. BJU Int. 89, 835-841 (2002). (Pubitemid 34535412)
99. Kane, S. Urogenital complications of Crohn's disease. Am. J. Gastroenterol. 101 (12 Suppl.), S640-S643 (2006). (Pubitemid 44902632)
100. Parmar, M. S. Kidney stones. BMJ 328, 1420-1424 (2004). (Pubitemid 38789199)
101. Ramos-Casals, M. et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86, 242-251 (2007). (Pubitemid 47067483)
102. Geissler, A. et al. Focal white-matter lesions in brain of patients with inflammatory bowel disease. Lancet 345, 897-898 (1995).
103. Singh, S., Kumar, N., Loftus, E. V. Jr & Kane, S. V. Neurologic complications in patients with inflammatory bowel disease: Increasing relevance in the era of biologics. Inflamm. Bowel Dis. 19, 864-872 (2012).
104. Zois, C. D., Katsanos, K. H., Kosmidou, M. & Tsianos, E. V. Neurologic manifestations in inflammatory bowel diseases: current knowledge and novel insights. J. Crohns Colitis 4, 115-124 (2010).
105. Bogenrieder, T., Rogler, G., Vogt, T., Landthaler, M. & Stolz, W. Orofacial granulomatosis as the initial presentation of Crohn's disease in an adolescent. Dermatology 206, 273-278 (2003). (Pubitemid 36407840)
106. Stubgen, J. P. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 37, 281-292 (2008).
107. Vadikolias, K. et al. Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn's disease. Eur. J. Gastroenterol. Hepatol 19, 159-162 (2007). (Pubitemid 46204334)
108. Ott, C., Liebold, A., Takses, A., Strauch, U. G. & Obermeier, F. High prevalence but insufficient treatment of iron-deficiency anemia in patients with inflammatory bowel disease: results of a population-based cohort. Gastroenterol. Res. Pract. 2012, 595970 (2012).
109. Voegtlin, M. et al. Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. J. Crohns Colitis 4, 642-648 (2010).
110. Bager, P. et al. The prevalence of anemia and iron deficiency in IBD outpatients in Scandinavia. Scand. J. Gastroenterol. 46, 304-309 (2011).
111. Hwang, C., Ross, V. & Mahadevan, U. Micronutrient deficiencies in inflammatory bowel disease: from A to zinc. Inflamm. Bowel Dis. 18, 1961-1981 (2012).
112. Leitgeb, C., Pecherstorfer, M., Fritz, E. & Ludwig, H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73, 2535-2542 (1994). (Pubitemid 24155530)
113. Gasche, C. et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm. Bowel Dis. 13, 1545-1553 (2007).
114. Kent, A. J., Blackwell, V. J. & Travis, S. P. What is the optimal treatment for anemia in inflammatory bowel disease? Curr. Drug Deliv. 9, 356-366 (2012).
115. Glass, G. B. & Mersheimer, W. L. Metabolic turnover of vitamin B12 in the normal and diseased liver. Am. J. Clin. Nutr. 8, 285-292 (1960).
116. Bjarnason, I. et al. Reduced bone density in patients with inflammatory bowel disease. Gut 40, 228-233 (1997). (Pubitemid 27093099)
117. Pigot, F. et al. Low bone mineral density in patients with inflammatory bowel disease. Dig. Dis. Sci. 37, 1396-1403 (1992).
118. Compston, J. E. et al. Osteoporosis in patients with inflammatory bowel disease. Gut 28, 410-415 (1987). (Pubitemid 17056874)
119. Bernstein, C. N., Leslie, W. D. & Leboff, M. S. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 124, 795-841 (2003). (Pubitemid 36268496)
120. Bernstein, C. N., Blanchard, J. F., Leslie, W., Wajda, A. & Yu, B. N. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann. Intern. Med. 133, 795-799 (2000).
121. Vestergaard, P. Prevalence and pathogenesis of osteoporosis in patients with inflammatory bowel disease. Minerva Med. 95, 469-480 (2004).
122. [No authors listed] American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 124, 791-794 (2003).
123. Reid, D. M. et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J. Bone Miner. Res. 15, 1006-1013 (2000). (Pubitemid 30350063)
124. Saag, K. G. et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N. Engl. J. Med. 339, 292-299 (1998). (Pubitemid 28366417)